Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P16220

UPID:
CREB1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P16220; P21934; Q6V963; Q9UMA7

BACKGROUND:
The protein Cyclic AMP-responsive element-binding protein 1, known for its phosphorylation-dependent transcriptional activation, is integral to the synchronization of circadian rhythms and adipose cell differentiation. Its function extends to modulating apoptotic and inflammatory responses in cardiomyocytes, triggered by ERFE-mediated AKT signaling.

THERAPEUTIC SIGNIFICANCE:
Given its genetic link to angiomatoid fibrous histiocytoma via the EWSR1/CREB1 fusion gene, CREB1 emerges as a critical molecular target in cancer research. The exploration of CREB1's functions and interactions offers promising avenues for the development of targeted therapies for cancer and other diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.